Circulating Biomarkers in Patients With Anal Cancer Treated With Induction Chemotherapy

Launched by AARHUS UNIVERSITY HOSPITAL · Feb 9, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the use of blood tests to help understand how well patients with anal cancer respond to a specific type of treatment called induction chemotherapy (ICT). The researchers want to see if measuring certain markers in the blood, particularly related to the human papillomavirus (HPV), can predict how effective the chemotherapy will be and how patients will do in the long run. The trial is focused on patients with locally advanced anal cancer or those with cancer that has spread to other areas, and it aims to gather important information that could help improve future treatments.

To be eligible for this trial, participants need to be at least 18 years old and have been diagnosed with squamous cell carcinoma of the anus, specifically those who will receive ICT before more intensive treatment options, like chemotherapy and radiation. Participants will need to provide consent and will be closely monitored throughout the study. Importantly, those who have had other cancers in the last five years (except for a specific type called basal cell carcinoma) or who cannot have blood drawn will not be able to participate. This trial is currently recruiting patients, and it offers a unique opportunity to contribute to important research that could benefit others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histological verified squamous cell carcinoma of the anus
• • Treatment with ICT prior to definitive CRT or RT due to locally advanced disease or
• • Patients with synchronous metastatic disease treated with ICT with the purpose of definitive CRT (potentially in combination with organ directed therapy (surgery, RFA, SBRT) for the metastatic sites)
• • Age ≥ 18 years
• • Written and orally informed consent
• Exclusion Criteria:
• • Contraindications for blood sampling
• • Other malignancy within the past five years, with exception of basal cell carcinoma